Neogen Chemicals Allots 10 Lakh Equity Shares Worth ₹161 Crore on Preferential Basis
Neogen Chemicals approved the allotment of 10,00,000 equity shares at ₹1,610 each, raising ₹161 crore. The shares are allotted on a preferential basis to Cadamba Solutions Private Limited, a promoter group member. The company's paid-up equity share capital has increased post-allotment.
The preferential allotment of ₹161 crore is a significant amount for the company, impacting its capital structure and potentially funding future growth, thus having a medium-term impact.
The company successfully raised capital through a preferential allotment, which is generally viewed positively as it strengthens the company's financial position and supports growth initiatives.
Neogen Chemicals Limited announced the outcome of its Fund Raising Committee meeting, held on April 18, 2026. The committee approved the allotment of 10,00,000 equity shares of face value ₹10 each at a price of ₹1,610 per share, including a premium of ₹1,600 per share.
This preferential allotment amounts to ₹161,00,00,000 (Rupees One Hundred and Sixty-One Crore only) and is made to Cadamba Solutions Private Limited, a Promoter Group Member. The meeting commenced at 1:30 p.m. and concluded at 1:40 p.m. on the same day.
Following this allotment, the company's issued, subscribed, and paid-up equity share capital has increased from ₹26,38,16,740 to ₹27,38,16,740. The newly allotted equity shares will be listed on BSE Limited and National Stock Exchange of India Limited and will rank pari passu with existing equity shares. The shares allotted to Cadamba Solutions Private Limited will be locked in for a period of 18 months from the date of trading approval.
What to do with a filing like this
Neogen Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neogen Chemicals Limited. Read the original for the full detail.